Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment…
| Periodo | 2015-08 | 2013-02 |
|---|---|---|
| Real | — | — |
| Estimado | $-5.58 | $-8.40 |
| Sorpresa | — | — |
| Métrica | ATHE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | — | -39.2% | — |
| ROA | -26.4% | -30.9% | +4.6% |
| Current Ratio | 12.98 | 2.73 | +10.25 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -26.4% | — |
| ✗Flujo de caja operativo positivo | −A$11M | −A$13M |
| ✓Rentabilidad sobre activos al alza | -26.4% | -99.5% |
| ✓Caja operativa/activos supera al ROA | -24.9% | ROA -26.4% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 12.98 | 3.54 |
| ✗Sin aumentar el nº de acciones | 6,397M | 3,649M |
| –Margen bruto al alza | — | — |
| –Rotación de activos al alza | — | — |
ALTERITY THERAPEUTICS LTD cotiza a 2.62 USD y tiene una capitalización bursátil de $47M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud